HHS purchases IV antiviral drug to treat monkeypox
The Department of Health and Human Services this week purchased $26 million worth of intravenous TPOXX (tecovirimat) to treat monkeypox, which the manufacturer expects to deliver next year. Under its contract with SIGA Technologies, HHS may still purchase additional oral and IV TPOXX, an antiviral drug approved by the Food and Drug Administration to treat smallpox and available under an investigational protocol to treat monkeypox. TPOXX is available free to states and territories through the Strategic National Stockpile, which held over 1.7 million treatment courses before the monkeypox outbreak. HHS last week declared the U.S. outbreak, which exceeds 10,000 cases, a public health emergency.
Related News Articles
Headline
President Trump signed an executive order Aug. 10 revamping the federal government’s recommended childhood vaccine schedule. The order divides immunizations…
Headline
The Food and Drug Administration Aug. 5 approved the first mRNA-based flu vaccine, called mFlusiva. The vaccine is manufactured by Moderna and was approved for…
Headline
Two individuals have died in Michigan in connection to the current multistate cyclosporiasis outbreak, the Michigan Department of Health and Human Services…
Headline
There have been 2,318 confirmed measles cases in the U.S. so far this year, the most in the country since 1991, according to the latest data from the…
Headline
The AHA’s Living Learning Network, in partnership with the Centers for Disease Control and Prevention, July 22 released “Rural Sepsis Care in Action: Real-…
Headline
A Centers for Disease Control and Prevention report released July 16 found that wastewater surveillance failed to detect an internationally circulating measles…